5 assets in Ovarian Germ Cell Tumor

Therapeutic assets addressing Ovarian Germ Cell Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Etoposide Ovarian Germ Cell Tumor	Nabil Adra	P3	BB (68)
Ipilimumab Ovarian Germ Cell Tumor	National Cancer Institute (NCI)	P2	B (59)
Cabozantinib Ovarian Germ Cell Tumor	Jennifer King	P2	CCC (53)
Nivolumab Ovarian Germ Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Xmab541 Ovarian Germ Cell Tumor	Xencor, Inc.	P1	CC (43)